Investigational drugs for HIV: trends, opportunities and key players.
Ronald J OvermarsZoë KrullaarsThibault MespledePublished in: Expert opinion on investigational drugs (2023)
While the field focuses on extending dosing intervals, we identify drug tissue penetration as an understudied opportunity to improve HIV care. We repeat that self-administration remains an essential milestone to reach the full potential of long-acting drugs. Treatments and prevention strategies based on broadly neutralizing antibodies require a deeper understanding of their antiretroviral properties.
Keyphrases
- hiv infected
- hiv positive
- human immunodeficiency virus
- antiretroviral therapy
- hiv aids
- men who have sex with men
- hiv testing
- hepatitis c virus
- hiv infected patients
- drug induced
- south africa
- dengue virus
- human health
- clinical trial
- phase ii
- emergency department
- zika virus
- adverse drug
- risk assessment
- climate change
- phase iii